Drugs / [225]-FPI-2059
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05605522 | Feb 2023 → Jul 2024 | Ewing sarcoma, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma +2 | 3B Pharmaceuticals GmbH | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [225]-FPI-2059 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05605522 ↗ |
| Modality | Small molecule | “NTSR1-targeting small molecule” NCT05605522 ↗ |
| Route | Intravenous | “Participants will be dosed through IV administration every 56 days up to four cycles.” NCT05605522 ↗ |
| Target | NTSR1 | “NTSR1-targeting small molecule” NCT05605522 ↗ |